Want to see SE:LARK full AI Analyst Report?
LARK Stock Chart & Stats
kr2.20
kr0.02(0.91%)
At close: 4:00 PM EDT
kr2.20
kr0.02(0.91%)
Day’s Range― - ―
52-Week Rangekr1.75 - kr2.87
Previous CloseN/A
Volume46.62K
Average Volume (3M)8.87K
Market Cap
kr46.14M
Enterprise Valuekr38.38
Total Cash (Recent Filing)kr6.17M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)39.3
Beta<0.01
Next Earnings
Feb 12, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield84.03%
Share Statistics
EPS (TTM)0.06
Shares Outstanding19,801,197
10 Day Avg. Volume4,316
30 Day Avg. Volume8,869
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.81
Price to Sales (P/S)0.00
P/FCF Ratio-3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free structure and substantial equity base reduce financial risk and provide resilience while the company advances its programs. This capital position can preserve strategic flexibility and limit financing pressure during continued research and development investment.
Revenue ReboundThe strong TTM revenue rebound indicates improved commercial or partnering-related activity compared with the prior period. If maintained, this growth can broaden the operating base and support progress toward a more durable financial profile, although profitability remains unresolved.
Focused Gene-Therapy ModelA focused neurological gene-therapy pipeline gives CombiGene a defined strategic direction and a business model centered on advancing candidates toward partnerships or licensing. Successful transactions could provide larger partners with commercialization resources beyond the company’s internal scale.
Bears Say
Persistent Cash BurnPersistent negative operating and free cash flow means the business is not yet self-funding its activities. Continued cash consumption can require additional capital or transactions to sustain development, reducing flexibility even though the balance sheet currently carries no debt.
Negative Core ProfitabilityPositive net income has not translated into sustainable operating earnings because gross and operating profit remain negative. This weak core profitability limits confidence in recurring earnings power and suggests that the reported improvement may not yet represent a durable operating turnaround.
Volatile ReturnsThe multi-year pattern of strongly negative return on equity followed by only a slight TTM improvement shows that shareholder returns have been inconsistent. Such volatility makes performance harder to rely on and indicates that the recent improvement has not yet been demonstrated across a sustained period.
LARK FAQ
What was CombiGene AB’s price range in the past 12 months?
CombiGene AB lowest stock price was kr1.75 and its highest was kr2.87 in the past 12 months.
What is CombiGene AB’s market cap?
CombiGene AB’s market cap is kr46.14M.
When is CombiGene AB’s upcoming earnings report date?
CombiGene AB’s upcoming earnings report date is Feb 12, 2027 which is in 147 days.
How were CombiGene AB’s earnings last quarter?
CombiGene AB released its earnings results on Aug 21, 2026. The company reported kr0.062 earnings per share for the quarter.
Is CombiGene AB overvalued?
According to Wall Street analysts CombiGene AB’s price is currently Overvalued.
Does CombiGene AB pay dividends?
CombiGene AB pays a Annually dividend of kr2 which represents an annual dividend yield of 84.03%. See more information on CombiGene AB dividends here
What is CombiGene AB’s EPS estimate?
CombiGene AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CombiGene AB have?
CombiGene AB has 19,801,197 shares outstanding.
What happened to CombiGene AB’s price movement after its last earnings report?
CombiGene AB reported an EPS of kr0.062 in its last earnings report. Following the earnings report the stock price went up 0.901%.
Which hedge fund is a major shareholder of CombiGene AB?
Currently, no hedge funds are holding shares in SE:LARK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CombiGene AB
Lärkberget AB (publ) functions as an investment firm, engaging in a variety of financial endeavors. Its operations encompass direct capital deployment into low-risk instruments, broader financial investments, acquiring stakes in privately held yet profitable companies, and serving as a vehicle for reverse acquisitions. Established in 1990 and based in Östermalm, Sweden, the company transitioned to its current name, Lärkberget AB (publ), in June 2025, having formerly operated as CombiGene AB (publ).